Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Single Oral Doses of Ozanimod in Healthy Chinese Adults
NCT04211558Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ozanimod in multiple sclerosis (MS) and ulcerative colitis (UC), sponsored by Celgene Corporation. Primary endpoints: Maximum Plasma Concentration at 14 days, Time to Maximum Plasma Concentration at 14 days and 6 more. Started Aug 2020; status: completed.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04211558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04211558.